Study of D-0502 for ER+ HER2- advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests an oral drug called D-0502 for people with a specific type of advanced breast cancer (ER-positive, HER2-negative). It is for those whose cancer has returned or worsened after hormone therapy, and it may be an option before trying more chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have ER-positive, HER2-negative breast cancer that has spread or cannot be removed by surgery.
- Your cancer must have returned or worsened while on, or after, hormone therapy.
- You can have had up to 2 prior chemotherapies for advanced disease.
- You must have at least one tumor that can be measured on a CT or MRI scan, or bone lesions that can be tracked.
- You should not have unstable or active brain metastases; stable brain metastases may be okay.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This trial tests a new drug, HRS-6209, combined with other treatments for people with hormone receptor-positive, HER2-negative cancer. The goal is to see if the combination is safe and works well.
This trial tests a new drug called ES2B-C001, with or without an adjuvant, to see if it is safe for people with HER2-positive breast cancer that has spread and has not responded to previous treatments.
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
This trial tests an experimental oral drug (FWD1802) for women with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to hormone therapy. It looks at whether the drug can slow or stop cancer growth, especially if you have an ESR1 mutation.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.